| Ticker: EXAC | 4613 N.W. 6th Street | |
| Exchange: NASDAQ-National Market | Gainesville, Florida 32609 | |
| Industry: Manufacturing | (352) 377-1140 |
| Type of Shares: | Common Shares | Filing Date: | 4/1/96 | |
| U.S. Shares: | 1,600,000 | Offer Date: | 5/30/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $6.75 - $8.75 | |
| Primary Shares: | 1,600,000 | Offer Price: | $8.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.68 | |
| Offering Amount: | $12,400,000 | Selling: | $0.38 | |
| Expenses: | $621,000 | Reallowance: | $0.10 | |
| Shares Out After: | 4,575,274 |
| Manager | Tier | Phone |
| First Equity Corporation of Florida | Lead Manager | (305) 379-0731 |
| Auditor: Deloitte & Touche | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $9.12 | $3.42 | $1.69 | Assets: | $11.67 |
| Net Income: | $0.83 | $0.31 | $0.12 | Liabilities: | $7.51 |
| EPS: | $0.27 | $0.10 | $0.04 | Equity: | $4.17 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company develops, manufactures, markets and sells orthopaedic implant devices and related surgical instrumentation to hospitals and physicians in the United States and overseas. The company's orthopaedic implant products are used to replace joints which have deteriorated as a result of injury or disease such as arthritis. Prior to 1995, the company's revenues were derived primarily from sales of its primary hip replacement systems. During 1995, the company introduced Optetrak, a total primary knee replacement system, which had been in development for three years. The Optetrak knee system was conceived by the company in collaboration with members of its Scientific Advisory Board in cooperation with the Hospital for Special Surgery, an internationally known hospital for orthopaedic surgery. The Optetrak system represents a highly differentiated product based on precision manufacturing techniques and a design which reduces articular contract stress. The Optetrak system is the most modern rendition of a series of knee implants which were first introduced in 1974 and are still being marketed by certain of the company's competitors. |
| Use of Proceeds |
| The proceeds from the offering will be used for the purchase of inventory, instruments and equipment, research and development, repayment of debt, redemption of preferred stock, and for working capital and for general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.